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Abstract: The encapsulation of doxorubicin in a pegylated liposomal matrix led to a 
reformulated agent with a different toxicity profile and improved clinical utility. Liposomal 
doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with 
predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to 
the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate 
into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this 
proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New 
combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable 
toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity 
profile renders liposomal doxorubicin an ideal partner for combination regimens with other 
cytotoxics, and more recently with biological agents. Such combinations are the subject of 
ongoing clinical trials.
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Introduction
The pivotal phase III trial of pegylated liposomal doxorubicin (PLD) in ovarian cancer 
published in 2001 confirmed the activity of this drug in second-line metastatic ovarian 
cancer (OC), demonstrating equivalent overall survival (OS) compared with topotecan 
in women with recurrent platinum-sensitive and resistant OC.1 A nearly 40-week 
advantage in OS over topotecan was noted in a planned subset analysis for patients 
with platinum-sensitive OC, indicating marked clinical efficacy in this subgroup. PLD 
toxicities included bone marrow suppression, mucositis, and extensive palmar-plantar 
erythrodysesthesia (PPE), or hand-foot syndrome, incidence of the latter approaching 
50%. Other reports note that PPE is not always limited to the hands and feet, but at 
times it results in diffuse skin involvement.2 However, safety studies have continued 
to show that the cumulative myocardial toxicity associated with doxorubicin (DOX) 
is avoided with the use of PLD.3
PLD serves as a prototype for the role of formulation in defining the clinical utility 
of chemotherapeutics, the reformulation of DOX in a pegylated liposomal matrix 
having increased its clinical utility, and abrogated some of its toxicities. However, 
while some of the adverse events typically associated with DOX are avoided by using 
the liposomal encapsulation, new and unique toxicities arise with PLD. This has been 
highlighted in reports of toxicities from phase II and III trials as well as in case reports 
and series. PLD avoids the cardiac toxicity typically associated with DOX, but has Therapeutics and Clinical Risk Management 2009:5 640
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well documented and predictable cutaneous toxicity. This 
review will provide a brief overview of the development and 
relevant clinical pharmacology of PLD, but will primarily 
focus on its clinical use in OC and the adverse events associ-
ated with this use.
A brief history of development
Liposomes are phospholipid bilayers engineered to form 
a vesicle or “nano-package”. The concept of liposomal 
encapsulation for drug delivery was originally proposed 
in the 1980s as a method to change the pharmacological 
properties of drugs, attempting to improve targeting to 
the tissue of interest, as well as to avoid toxicities.4 It was 
originally thought that this technology would offer a number 
of advantages. Longer exposure in vivo would result from 
protection of the active compound from metabolism and 
excretion. More targeted therapy would result from endocy-
tosis of the active compounds at the site of action, thereby 
limiting exposure to nontarget tissues. This in turn would 
lead to minimization of off-target toxicity, as a result of the 
drug being delivered primarily to the tissue of interest. These 
advantages were, and remain, particularly appealing for drugs 
that have narrow therapeutic indices, severe toxicities, and/or 
are unstable in vivo. The reformulation of drugs in liposomes 
is still an active area of pharmaceutical development, as is 
the engineering of optimal liposomes.
Chemotherapeutics were appealing from the outset for 
liposomal encapsulation as a pharmacologically active set 
of compounds with many off-target toxicities.5,6 DOX, an 
anthracycline active in a broad variety of tumors but with a 
life-time cumulative dose cardiotoxicity, was an early can-
didate drug explored for this new formulation.7 The in vitro 
development of the liposomal carrier for DOX encountered 
several hurdles in early development related to stability of the 
matrix. Unstable formulations resulted in drug leakage; on the 
opposite extreme, matrices too avid for the active compound 
prevented its release at the intended site of action.8,9
Different formulations of liposomes, and/or addition of 
various compounds to liposomes, impart differing proper-
ties to the end-products. To evade rapid recognition and 
uptake by the reticular-endothelial system, liposomes were 
engineered by adding a polyethylene glycol hydrophilic 
polymer layer, or PEG.10 The final compounds are referred to 
as pegylated, sterically stabilized, or STEALTH liposomes. 
These pegylated liposomes display reduced rates of uptake 
by the liver and remain in circulation for longer periods 
compared to conventional liposomes. The physio-chemical 
properties and manufacturing process for the commercially 
available formulations of PLD were excellently reviewed 
by Gabizon.11
Pharmacokinetic properties
Preclinical work in cancer mouse models offered insight 
into the pharmacokinetic and pharmacodynamic changes 
conferred by the pegylated liposomal encapsulation to DOX. 
Early work indicated improved targeting of the compound 
to tumors, allowing enhanced uptake by cancer cells, and 
increased extravasation at the tumor site, but these proper-
ties were not reported consistently.12–14 An important finding 
was that the liposomal encapsulation of the drug resulted in 
increased DOX exposure, measured as the total area under 
the curve (AUC). In one report the AUC for liposomal DOX 
(not pegylated) and for PLD were 2.6- and 6.8-fold higher 
than for DOX. This change likely arose from a progressive 
decrease in half-life in plasma from 23.7 ± 5 hours for DOX, 
to 26 ± 3 and 46 ± 14 hours for liposomal DOX and PLD, 
respectively.15
One of the major reasons for exploring liposomal 
encapsulation of chemotherapeutics in general, and DOX in 
particular, was to change the pharmacokinetic properties of 
the drug, the concept being that encapsulation in a liposome 
would allow greater exposure of the target to the drug. Early 
human studies supported this idea, with the early studies 
showing a nearly 300-fold increase in AUC for liposomal 
doxorubicin compared to the free drug.16 Modifications of the 
liposomes’ formulation affects their pharmacokinetic proper-
ties, specifically the release rate of the active compound from 
the liposome, and the rate at which the liposome is cleared.17,18 
Free DOX has a reported clearance of approximately 50 L/h, 
with a volume of distribution of approximately 9 L.19,20 
By comparison, for the dosing range of 40 to 60 mg/m2, 
PLD has a reported clearance of 0.02 to 0.07 L/h/1.7 m2 and 
a volume of distribution 2 to 10 L/m2.11
Scarce information is available on pharmacokinetic 
properties of PLD in special populations. While no studies 
to date have explored PLD disposition in the elderly, the 
effects of age and end-organ dysfunction were explored 
in a study in which 29 patients with chronic renal insuffi-
ciency (90 mL/min) were treated with PLD. Because the 
median age in this study was 70 years, the influence of age 
was indirectly addressed. The study reported a slight, but 
not statistically significant increase in adverse events in the 
elderly, and a significantly increased need for dose reductions 
in patients with impaired renal function.21
For repeated administration, preclinical experiments in 
rat models have shown that the clearance of PLD is increased Therapeutics and Clinical Risk Management 2009:5 641
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after repeated dosing; however the mechanism for this was 
not determined.22 In humans, the opposite occurs; repeated 
dosing results in a decline in PLD clearance between the 
first and third cycles.23 This becomes relevant in that repeat 
administration of PLD may result in increased exposure to the 
drug, and hence, increased toxicity as its clearance declines 
with each cycle.
Few reports demonstrated sequence-dependence in the 
disposition of agents administered in combination with 
PLD, suggesting a potential for drug–drug interactions. For 
instance, the administration of PLD with vinorelbine led to 
a sequence-dependent change in vinorelbine distribution. 
If PLD was given first, the exposure to vinorelbine increased 
compared to the reverse sequence. The authors postulated 
that PLD may act as a p-glycoprotein (MDR1) inhibitor, thus 
reducing the excretion of vinorelbine.24
Phase I and II development of PLD
Initial studies of a liposomal encapsulation of DOX were 
reported by a group from the Royal Liverpool Hospital. They 
administered liposome-encapsulated DOX to 6 patients with 
hepatic metastases from gastrointestinal adenocarcinomas 
and recorded one objective response and absence of the 
typical doxorubicin induced toxicity.25 This led to several 
phase I trials which found that the dose of a liposome-
encapsulated doxorubicin could be driven up significantly 
higher compared to free DOX.26 The maximal dose reached 
with this formulation was 120 mg/m2 given every 3 weeks; 
however this was associated with substantial bone-marrow 
suppression, particularly neutropenia, as well as stomatitis 
and alopecia.27
After early indicators of success in gynecologic malignan-
cies, a phase II study evaluated PLD in ovarian cancer.28–30 
Forty-eight patients with OC, previously treated with 
paclitaxel and platinum, were treated with PLD administered 
at a dose of 50 mg/m2 every 28 days. The objective response 
rate (RR) in this trial was 19%, and toxicities consisted of 
neutropenia, thrombocytopenia, and stomatitis.29
Interestingly, while it has been shown that PLD has linear 
dosing when administered in the range of 30–60 mg/m2, ie, 
increases in dose correspond to increased exposure in vivo, 
it has been also shown that a reduction in the dose of PLD 
reduces toxicity, but has no adverse effect on response. 
Much of the original work dosed PLD at 50 mg/m2; however, 
retrospective analyses, followed by prospective validation, 
showed that the dose could be reduced to 40 mg/m2 with-
out loss of efficacy but with reductions in the incidence of 
adverse events. A retrospective analysis of patients treated 
with PLD between 1997 and 1998 at 40 mg/m2 every 28 days 
revealed a pattern of activity similar to what is expected at 
the higher dose of 50 mg/m2, but with reduced toxicities.31 
Of 72 patients treated, 27% had objective responses, while 
grade 3–4 hematologic toxicities occurred only in a minority 
of patients: 1 case of neutropenia, 1 case of thrombocytopenia, 
and 8 cases of anemia.31 Mucositis and PPE were observed in 
3 and 6 patients, respectively. A second retrospective analysis 
supported these findings, and confirmed marked decreases in 
skin toxicity with reduced PLD dosing.31,32 This led to a phase 
II study performed through the Gynecologic Oncology Group 
(GOG) testing the activity and toxicity of PLD at 40 mg/m2 
in women with mixed gynecologic tumors. This study 
reported that women treated at this lower dose had similar 
response rates, but reduced toxicity compared to historical 
controls treated with the higher PLD dose33. The reported 
rate of PPE was 18%, but no patients suffered from grade 
3–4 hand-foot syndrome and only 8% of patients developed 
mucositis, none of which was grade 3–4. These observations 
formed the basis for the lower dose selection in future phase 
III trials testing PLD, including the Multicentre Italian Trials 
in Ovarian Cancer Group (MITO-3) trial discussed below. 
Likewise, biweekly administration of PLD at a dose of 
20 mg/m2 led to reduced cutaneous toxicity, while retain-
ing efficacy in relapsed ovarian cancer. Two phase II trials 
testing this schedule of administration reported grade 3 PPE 
in less than 5% of patients and preserved clinical activity.34,35 
A randomized comparison against the standard PLD dose 
has not been performed.
The fundamental markers for clinical activity in oncology 
trials are objective RR and/or survival. However, surrogate 
markers are sometimes pursued as a method for early insight 
into determining response. A commonly followed biomarker 
in ovarian cancer trials is CA-125, a glycoprotein secreted 
by cancer cells.36 The relationship between the efficacy of 
PLD and CA-125 concentration changes has been exten-
sively explored. Interestingly, several studies have supported 
the idea that the response of CA-125 in patients receiving 
PLD may be delayed by as many as 3 cycles of therapy. 
In a retrospective analysis of 59 women who received PLD, 
it was observed that treatment discontinuation for increases in 
CA-125 were common. However, in those women who had a 
clinical response, CA-125 declines were not noted until cycle 
3 or later.37 Another study of 239 women treated with PLD 
also found that early variance in CA-125 levels did not corre-
late with clinical benefit, as up to 10% of responders displayed 
increases in CA-125 concentrations of up to 25% during the 
first several cycles.38 However, in a trial of 120 women who Therapeutics and Clinical Risk Management 2009:5 642
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had received either topotecan or PLD, consecutive increases 
in CA-125 across multiple cycles correlated with a decreased 
likelihood of response and all 54 responders had decreased 
CA-125 levels by the second cycle.39 These observations 
indicate that early variations in CA125 levels in patients 
treated with PLD should be interpreted within the context 
of clinical and radiographic findings for each case.
Phase III trials
Prior to the FDA-approval of PLD for recurrent OC, the 
accepted standards for second-line treatment of recurrent 
ovarian cancer included topotecan and paclitaxel. Response 
rates to these second-line agents ranged between 19% and 
29% for platinum-sensitive OC and 12% to 14% for women 
with platinum refractory OC.40,41 The testing and introduction 
of PLD set a new standard, particularly in terms of durability 
of response, as response rates to PLD were not markedly dis-
similar from those of older single agent regimens investigated 
in this setting.
The pivotal phase III trial reported by Gordon compared 
PLD to topotecan in women with recurrent OC.1 Patients 
were stratified based on platinum resistance (disease progres-
sion within 6 months of platinum-containing regimen) and 
bulkiness of disease (tumor mass 5 cm). Between May 
1997 and March 1999, 481 patients were enrolled on this 
trial. Seven patients never received drug after enrollment; 
therefore 474 were analyzed, 235 on the topotecan arm, 
and 239 on the PLD arm. Percentages of patients with plati-
num-resistant OC and bulky disease were similar between 
arms. The topotecan arm included 47% patients with bulky 
disease and 53% with platinum-resistant OC, and the PLD 
arm included 46% and 54% in these respective categories. 
Evaluation of OS, as the primary endpoint of the study, found 
no significant differences between the study arms. The OS 
on the PLD arm was 60 weeks, not significantly improved 
over the topotecan arm 56.7 weeks. However, in a planned 
subset analysis, there was a significant difference between 
the two arms for patients with platinum-sensitive OC. In this 
patient population, the OS of patients treated with PLD was 
108 weeks, compared to 71.1 weeks for women treated with 
topotecan (P = 0.008), suggesting an increased benefit of 
PLD in this subgroup of patients.
A 4-year follow-up of this trial revealed long-term 
survival advantage for the PLD arm, regardless of the 
platinum-resistance status.40 Patients who had received 
PLD had an OS of 62.6 weeks compared to 59.7 weeks for 
those patients who had received topotecan (P = 0.05). This 
follow-up emphasized further the benefits of PLD in patients 
with platinum-sensitive OC, with an OS of 107.9 weeks in 
this group as compared to 70.1 weeks for patients treated 
with topotecan (P = 0.017). Further analysis of prognostic 
variables (age, performance status at enrollment, bulkiness 
of disease) found no other significant predictors of clinical 
benefit. Adverse events were common, with essentially all 
patients reporting toxicities. However, overall grade 4 events 
were more common in the topotecan arm (71% vs 17%). The 
most common PLD toxicities included PPE (49%) and stoma-
titis (40%). The results of this study led to the FDA-approval 
of PLD for the second-line treatment of recurrent OC.
PLD has been subsequently compared to gemcitabine in 
2 randomized phase III trials. In the trial reported by Mutch, 
patients with recurrent OC, fallopian tube, or peritoneal 
cancer who had received at least 1, but no more than 2 
prior lines of therapy, including a platinum-based regimen, 
were randomized to either gemcitabine at 1000 mg/m2 
on days 1 and 8 on a 21-day cycle, or to PLD at 50 mg/m2 
day 1 on a 28-day cycle.41 From 2002 to 2004, 194 women 
were enrolled on this trial, 99 on the gemcitabine, and 96 on 
the PLD arm. The arms of the trial were well balanced on 
disease burden, performance status, platinum responsiveness, 
and prior exposure to taxanes. There were no statistical 
differences between the two arms for median OS (12.5 vs 
13.5 months, P = 0.99) or progression-free survival (PFS, 
3.6 vs 3.1 months, P = 0.87).
Toxicity assessment revealed toxicities specific to each 
arm. Gemcitabine's common toxicities included constipation, 
fatigue, nausea/vomiting, and neutropenia. PLD’s common 
toxicities were fatigue, mucositis, and neutropenia. Among 
grade 3–4 toxicities on either arm, neutropenia was more 
common in gemcitabine-treated patients (38 vs 18 patients, 
P = 0.003), and PPE and mucositis were more common 
for those on PLD (10 vs 0 patients, and 3 vs 1 patients, 
respectively). Interestingly, as this trial allowed crossover at 
progression, 13 of the 66 women who crossed over from PLD 
to gemcitabine developed grade 2–3 PPE. This phenomenon 
likely represented a late toxicity of PLD, given that most 
of these cases occurred early after crossover (on day 1 of 
gemcitabine).41
Another trial comparing PLD to gemcitabine was 
MITO-3.42 The design of MITO-3 was similar to the study 
presented by Mutch, except for a different PLD dose (40 mg/
m2, as opposed to 50 mg/m2) and restriction of prior therapy 
to 1 regimen. Cross-over was not allowed, and assessment of 
response was based on RECIST.43 Treatment regimens were 
PLD at 40 mg/m2 day 1 on a 28-day cycle, and gemcitabine 
at 1000 mg/m2 given on day 1, 8, and 15 on a 28-day cycle.Therapeutics and Clinical Risk Management 2009:5 643
PLD in ovarian cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
One hundred and fifty-three patients were enrolled, with 
77 randomized to gemcitabine and 76 randomized to PLD. 
The primary endpoint of the study was time to progression 
(TTP), and secondary endpoints included OS, safety, quality 
of life, and RR. Patients were well matched for age, stage of 
disease and, histological subtypes. A slightly higher num-
ber of patients with suboptimal debulking were enrolled in 
the gemcitabine arm (54 vs 49), and the median CA-125 
concentration on enrollment was higher in the gemcitabine 
arm (243 vs 165 U/mL). Patients on both arms received a 
median of 4 cycles of therapy. The objective RR was higher 
for gemcitabine (29% vs 16%), TTP favored gemcitabine 
(20 vs 16 weeks), and the duration of response was equivalent 
between arms (18 weeks). However, OS assessment favored 
PLD (56 vs 51 weeks, P = 0.048), with the curves between 
the two arms separating out at approximately 48 weeks.
Toxicities were roughly equivalent, with increased 
neutropenia for gemcitabine (6% for PLD vs 23% for gem-
citabine) and increased PPE for PLD (5% for PLD vs 0% for 
gemcitabine). Quality-of-life (QoL) assessments performed 
on 79% of patients, at baseline and prior to each cycle of 
therapy, revealed equivalence at the 1st and 4th time-points, 
but superior QoL in PLD-treated patients at cycles 2 and 3 
(P  0.05). This may reflect better tolerance of PLD as over-
all toxicity on the PLD arm occurred in less than 10% of 
enrolled patients. Table 1 summarizes clinical outcomes and 
Table 2 summaries toxicities in phase III trials testing PLD 
administered as single agent. These trials have consolidated 
the role of PLD as preferred therapy for recurrent OC and 
positioned it as the standard for testing of new agents in this 
setting. Indeed, PLD has been used as the comparator arm 
in other phase III trials testing new single-agent chemothera-
peutics, such as canfosfamide and patupillone in women with 
recurrent OC (unpublished results).
PLD toxicity profile
PLD has a different toxicity profile compared to the anthra-
cycline base. The toxicities of the parent drug included the 
commonly observed hematologic and mucous membrane 
toxicities associated with most chemotherapeutics, as well 
as the unique and life-time dose-limiting cardiac toxicity at 
doses above 450 to 500 mg/m2.44 It was this unique toxicity 
that drove much of the initial safety assessment of PLD. 
Importantly, thorough early investigations including endo-
myocardial biopsies found no evidence of cardiac damage 
with PLD.45 Safety was further confirmed for prolonged 
PLD administration, no evidence of cardiac damage being 
observed when PLD was administered for more than 6 cycles.3 
Finally, in a study with longer follow up, 14 patients exposed 
to a median life-time dose of 685.5 mg/m2 did not develop 
cardiac dysfunction by echocardiogram, nor developed symp-
tomatic congestive heart failure.46 While not definitive, and 
in need of confirmation in a larger study population, it does 
appear that the cardiac toxicities associated with free DOX 
Table 1 Phase iii trials with pegylated liposomal doxorubicin (PLD) for recurrent/refractory ovarian cancer (OC)
Author Trial details Arms Eligibility Outcomes
Gordon et al 20011 Randomized
Multi-center
Open-label
Second line
Topo 1.5 mg/m2/day ×   
5 days 
PLD 50 mg/m2  
day 1 every 28 days
Recurrence after 
platinum based therapy 
No prior exposure to 
either agent
N = 474
Topo (235) PLD (239)
Median PFS (weeks) 17 16.1
Median OS (weeks) 56.7 60
Platinum-sensitive 
Median PFSa (weeks)
23.3 28.9
Platinum-sensitive 
Median OSb (weeks)
71.1 108
Mutch et al 200741 Randomized
Multi-center
Second line
Allowed cross over 
at progression
PLD 50 mg/m2  
day 1 every 28 days
Gem 1000 mg/m2,  
days 1 and 8
Recurrence after first-line
Platinum based therapy
No prior exposure to 
either agent
N = 195
Gem (99) PLD (96)
Median PFS (months) 3.6 3.1
Median OS (months) 12.7 13.5
Ferrandina et al 200842 Randomized
Multi-center
Second line
Gem 1000 mg/m2  
days 1, 8, and 15
PLD 40 mg/m2 every  
28 days
Recurrence within 
12 months after CT
No prior exposure to 
either agent
N = 153
Gem (77) PLD (76)
Median PFS (weeks) 20 16
Median OS (weeks)c 51 56
aP = 0.037, bP = 0.008, cP = 0.048, all other results not significant.
Abbreviations: Gem, gemcitabine;   Topo, topotecan; OS, overall survival; PFS, progression-free survival.Therapeutics and Clinical Risk Management 2009:5 644
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are not shared by PLD. Importantly, cardiac toxicity has not 
emerged during investigation of PLD in phase III trials,40,41,47 
but these trials limited the amount of PLD delivered to a 
maximum of 6 cycles.
Toxicities relatively unique to PLD include mucocutane-
ous toxicities, the most prominent being PPE or hand-foot 
syndrome. Rarely reported with DOX, the incidence and 
severity of PPE is much greater with the use of PLD. Erythema 
and pain to the palms and/or soles can progress to desqua-
mation reminiscent of burns. This is thought to be related to 
prolonged exposure generated by PLD compared to DOX, 
which is cleared more rapidly.48,49 The extreme form of this 
syndrome includes diffuse skin involvement, a syndrome 
referred to as diffuse toxic erythema.2 Based on phase III trial 
reports, the incidence of PPE ranges from 10% in the trial 
reported by Mutch to 50% in the pivotal phase III trial.1,41 
However, more recent studies noted a decreased incidence 
of PPE at 5% when the reduced dosing of PLD was used, 
ie, 40 mg/m2 in the trial reported by Ferrandina.42 Outside of 
clinical trials, there are few data on the incidence of PPE in 
community practice. One report examining the association 
between PPE and body mass index (BMI) in 108 women 
receiving PLD for gynecologic malignancies recorded a 14% 
incidence of grade 3 PPE.50 Interestingly, there was no correla-
tion between development of PPE and BMI in this analysis.
The pathophysiology of PPE has not been fully estab-
lished, although it was speculated that increased excretion of 
PLD through sweat glands, which is enhanced by increased 
temperature may be a contributor.51 Several publications have 
presented risk factors for cutaneous toxicity induced by PLD. 
Strong evidence supports that overall amount of exposure 
to PLD correlates with toxicity. In a dose-escalation trial 
with single agent PLD, increases in exposure as measured 
by AUC, were associated with progressive increases in the 
rate of PPE.13
Several trials have investigated potential preventative 
regimens for PPE, including regional cooling, application 
of topical dimethyl sulfoxide (DMSO), and dose reduction 
as previously discussed.52 Regional cooling, achieved with 
the use of ice packs on extremities, was tested in 20 women, 
of which 17 underwent cooling procedures and 3 received 
routine care. The incidence of grade 3–4 PPE was 6% in the 
women undergoing cooling compared to 67% in the untreated 
group. While interesting, this report has limitations related 
to the small cohort size and the broad range of PLD doses 
administered (30 to 50 mg/m2). Given the known association 
between the amount of drug exposure and development of 
PPE, the conclusions of the study remain, at most, hypothesis 
generating. The use of topical DMSO as a treatment modality 
was reported in two patients, who experienced resolution of 
grade 3 PPE after four-times daily applications of topical 
DMSO.53 Based on these limited data, it remains unclear 
whether there is a role for topical DMSO in the treatment of 
PPE. Other interventions used for the management of PPE 
include topical or systemic corticosteroids and pyridoxine 
(vitamin B6).54 The role of pyridoxine in preventing hand-
foot syndrome in patients treated with PLD was examined 
prospectively in a placebo-controlled randomized trial led 
by the Case Cancer Center that recently completed accrual 
(not reported).
In addition to PPE, a variety of other cutaneous toxicities 
have been reported, including granular parakeratosis, 
Table 2 Adverse events reported in phase iii trials with pegylated liposomal doxorubicin (PLD)
Study Grade 3–4 hematological toxicity Grade 3–4 nonhematological toxicity
Gordon et al 20011 Neutropenia
Anemia
Thrombocytopenia
12%
5%
1%
PPe
Stomatitis
23%
8.3%
Mutch et al 200741 Neutropenia
Febrile neutropenia
Anemia
Thrombocytopenia
18%
4%
2%
5%
PPe
Mucositis
10.4%
3.1%
Ferrandina et al 200842 Neutropenia
Anemia
Thrombocytopenia
6%
5%
0%
PPe
Stomatitis
5%
3%
Pignata et al 200683 Neutropenia
Anemia
Thrombocytopenia
46%
16%
26%
PPe
Stomatitis
2%
0
Abbreviation: PPe, plantar palmar erythema.Therapeutics and Clinical Risk Management 2009:5 645
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radiation recall, and other skin manifestations of toxicity.32,55,56 
Ageusia, or loss of sense of taste, was reported in one case 
and interestingly, resolved when treatment was switched to 
conventional DOX.57
Ongoing development of PLD
The strategy searching for synergy between PLD and 
other chemotherapeutics followed a similar course as the 
development of other combination regimens in oncol-
ogy, with a large number of phase I trials reported, but 
only few combinations advancing to phase II and III 
development. In phase I work, PLD was combined with 
ifosphamide,58 topotecan (oral59 or intravenous60–62), etoposide,63 
taxanes,64–67 platinums,68–71 vinorelbine,24,72 gemcitabine,73,74 and 
capecitabine.75 These trials are reviewed in Table 3, which 
summarizes the relevant maximum tolerated dose toxicities. 
However, in spite of generally positive reports, only a 
few combinations have advanced to phase II evaluation. Table 4 
presents important phase II combination regimens of PLD with 
topotecan, vinorelbine, platinums, and gemcitabine.
Table 3 Phase i combinations with pegylated liposomal doxorubicin (PLD)
Agent combined Maximum tolerated dose Dose-limiting toxicities Reference
ifosphamide PLD 40 mg/m2 day 1
ifos 1500 mg/m2/day Days 1–3
Neutropenia Bourgeois et al 200658
Topotecan (po) PLD 40 mg/m2 day 1
Topo 1.53 mg/m2/day Days 1–5
Neutropenia Rose et al 200859
Topotecan PLD 40 mg/m2 Day 4
Topo 1.25 mg/m2/day Days 1–3
Neutropenia death Garcia et al 200560
Topotecan PLD 40 mg/m2 day 1
Topo 0.4 mg/m2/day Days 1–14
Neutropenia 
thrombocytopenia diarrhea
Mirchandani et al 200562
Topotecan PLD 35 mg/m2 day 1
Topo 0.5 mg/m2/day Days 1–5
Neutropenia Ghesquieres et al 200661
etoposide (po) PLD 20 mg/m2 day 1
Topo 50 mg/m2/day Days 1–15
Hematologic not specified Rose et al 200263
Paclitaxelb PLD 30 mg/m2 day 1 
or 
Pac 90 mg/m2 weekly 4/6 weeks
Neutropenia PPe DvT Briasoulis et al 200465
PLD 35 mg/m2 day 1 
Pac 80 mg/m2 weekly 4/6 weeks
Paclitaxelb PLD 10 mg/m2 Day 1 
Pac 80 mg/m2 weekly 4/6 weeks
Neutropenia diarrhea Androulakis et al 200264
Paclitaxel PLD 15 mg/m2 day 1 
Pac 115 mg/m2 days 1 and 15
Neutropenia cardiac arrest Mavroudis et al 200267
Docetaxel PLD 20 mg/m2 days 1 and 15 
Doc 40 mg/m2 days 1 and 15
Skin toxicity 
thrombocytopenia
Fracasso et al 200366
Doc 35 mg/m2 days 1 and 15 
PLD 20 mg/m2 days 1 and 15
Oxaliplatina PLD 40 mg/m2 day 1 
Ox 130 mg/m2 day 1
Neutropenia 
thrombocytopenia
Recchia et al 200369
Carboplatinc PLD 35 mg/m2 day 1 
Carbo AUC 5 day 1
Neutropenia 
thrombocytopenia
Goncalves et al 200370
Cisplatin PLD 50 mg/m2 day 2 
Cis 60 mg/m2 day 1
Neutropenia Tas et al 200871
vinorelbinea PLD 30 mg/m2 day 1 
vin 25 mg/m2 days 1 and 8
Neutropenia Tambaro et al 200372
Gemcitabine PLD 20 mg/m2 days 1 and 15 
Gem 2000 mg/m2 Days 1 and 15
Rash stomatitis Fracasso et al 200273
Capecitabine (PO)a PLD 40 mg/m2 day 1 
Cap 1500 mg/m2 days 1–14
PPe asthenia Maltezos et al 200575
a3-week cycle, b6-week cycle, c3- or 4-week cycle (if not specified, 4-week cycle).
Abbreviations: Carbo, carboplatin; Cis, cisplatin;   vin, vinorelbine; Pac, paclitaxel;   Topo, topotecan; DvT, deep vein thrombosis; PPe, plantar palmar erythema.Therapeutics and Clinical Risk Management 2009:5 646
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Table 4 Phase ii combination regimens with pegylated liposomal doxorubicin (PLD) in ovarian cancer (OC)
Combination Study population Results Grade 3–4 
toxicities
Reference
PLD (30 mg/m2) day 1
Topotecan (1 mg/m2) days 1–5
every 3 weeks
N = 27  
platinum refractory
RR = 28%
SD = 44%
TTP = 30 weeks
Hematologic: 70% verhaar-Langereis 
et al 200676
PLD (30–35 mg/m2) day 1
Oxaliplatin (70 mg/m2) day 2
every 4 weeks
N = 43  
platinum sensitive (29)  
and refractory (14)
RR = 54%
SD = 29%
TTP = 10.2 mos
Neutropenia 12% Nicoletto et al 200678
PLD (20 mg/m2) days 1 and 2
Oxaliplatin (60 mg/m2) day 1  
and 2; every 3 weeks
N = 40  
recurrent OC
RR = 67%
SD = 25%
Neutropenia 37% Recchia et al 200779
PLD (30 mg/m2) day 1
Carboplatin (AUC 5) day 1
every 4 weeks
N = 104  
recurrent OC
RR = 62.5%
SD = 19%
TTP = 9.4 mos
Hematologic 51% Ferrero et al 200780
PLD (30 mg/m2) day 1
Carboplatin (AUC 5) day 1
every 4 weeks
N = 31  
platinum-sensitive
RR = 52%
TTP = 12 mos
Hematologic 81% Alberts et al 200881
PLD (40 mg/m2) day 1
Carboplatin (AUC 6) day 1
every 4 weeks
N = 67  
recurrent OC
RR = 68%
TTP = 11.6 mos
Neutropenia 24%
Fatigue 12%
Pain 10%
du Bois et al 200782
PLD (30 mg/m2) day 1
vinorelbine (30 mg/m2) day 1
every 3 weeks
N = 30  
recurrent OC
RR = 37%
SD = 10% 
TTP 5.5 mos
Neutropenia 12%
PPe 7%
Stomatitis 7%
Katsaros et al 200477
PLD (30 mg/m2) day 1
Gemcitabine (1000 mg/m2)
Days 1 and 8 every 3 weeks
N = 67  
recurrent OC
RR = 34.3%
SD = 38.8%
TTP = 28 weeks
Neutropenia 7%
PPe 10%
Stomatitis 10%
D’Agostine et al 200383
PLD (20 mg/m2) days 1 and 15 
Gemcitabine (2000 mg/m2)
Days 1 and 15 every 4 weeks
N = 18  
platinum refractory
RR = 28%
TTP = 17 mos
Anemia 17% Tas et al 200874
Notes: SD, stable disease;   TTP, time to progression.
Abbreviation: RR, response rate.
In phase II combination therapy trials, PLD has 
been dosed at 30 mg/m2, which represents 60% of the 
FDA-approved PLD dose for OC. The combination with 
topotecan induced a RR of 28%, but also marked grade 
3 and 4 hematologic toxicity (70%),76 reducing enthusi-
asm for further development of this regimen. A natural 
combination for PLD was that with the platinum agents, 
oxaliplatin, and carboplatin. The combination with 
oxaliplatin was well tolerated, with grade 3 and 4 hemato-
logic toxicities in the 20% to 30% range, and RR of 54% 
to 67%.78,79
At least 3 phase II trials have investigated PLD/
carboplatin combinations. Two trials combined PLD with 
carboplatin dosed to AUC 5 and reported RRs of 52% to 
62%.80,81 The third trial dosed carboplatin at an AUC of 6 
and reported slightly higher RR of 68%.80–82 TTP was similar, 
ranging between 9 and 12 months. This work, indicating 
interesting clinical activity of this combination in OC, led 
to its testing in phase III combination trials.
The Multicentre Italian Trials in Ovarian Cancer-2 
(MITO-2) investigated PLD in combination with carboplatin 
in the first-line setting. In this trial, both arms include carbopl-
atin given at an AUC of 5, with the control arm administering 
paclitaxel at 175 mg/m2, and the experimental arm using PLD 
at 30 mg/m2, both on a 21-day cycle. The trial completed 
enrollment in the last quarter of 2007 and initial results on 
50 patients were reported the same year. The RR for patients 
receiving carboplatin/PLD was 68% and additional 20% 
of patients had stable disease.84 An interim safety analysis 
of MITO-2 was released in 200685 and updated results 
were presented in 2009.86 Hematologic toxicities occurred 
frequently in both arms; grade 3–4 neutropenia in 43% of 
patients on the carboplatin/PLD arm and 49% of patients 
receiving carboplatin/paclitaxel (CT), grade 3–4 thrombocy-
topenia in 16% of patients receiving carboplatin/PLD vs 2% 
of patients on the standard arm (P  0.001), and grade 3–4 
anemia in 10% of patients on the experimental arm versus 
4% of patients receiving CT (P  0.001). Nonhematologic Therapeutics and Clinical Risk Management 2009:5 647
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toxicities included stomatitis and skin toxicity more common 
in the carboplatin/PLD arm (20% each, P  0.001) and 
neurotoxicity, alopecia, and diarrhea more frequent with the 
CT regimen. Although final results on OS and PFS are not 
yet available, early indicators of clinical activity in this trial 
show similar rates of RR (57% vs 59%) and stable disease 
(31% vs 29%),86 suggesting that perhaps carboplatin/PLD 
may become an alternative treatment for upfront treatment 
of patients with OC. Other trials investigating the carbopla-
tin/PLD combination include the ongoing Calypso phase III 
trial comparing CT to carboplatin/PLD in platinum-sensitive 
recurrent OC, run by the Gynecologic Cancer InterGroup 
(GCIG,), and the GOG protocol 182.
The Calypso trial, reported earlier in 2009, enrolled 
976 patients with platinum-sensitive recurrent OC.87 Similar 
to the MITO-2 trial, rates of grade 3–4 stomatitis (13%) and 
hand foot syndrome (11%) were higher in the carboplatin/
PLD arm, but alopecia, carboplatin hypersensitivity 
reactions, and peripheral neurotoxicity were significantly 
lower compared to those induced by the CT regimen. The 
median PFS was 11.3 months for carboplatin/PLD compared 
to 9.4 months for the standard regimen (P  0.001), position-
ing this regimen as a viable and less toxic alternative to CT 
in the setting of first platinum-sensitive OC recurrence.
In protocol GOG 182/ICON5, the combination carboplatin 
with paclitaxel (CT) and PLD was tested against the standard 
adjuvant regimen CT and 3 other regimens incorporating 
either topotecan or gemcitabine along with CT. In this arm, 
PLD was given at 30 mg/m2 every other cycle along with 
standard doses of CT. Of 862 patients randomized to this 
regimen, 658 completed 8 cycles of therapy.88 The median 
PFS of patients treated with CT/PLD was 16.4 months and the 
median OS was 42.8 months, not different from the standard 
arm or from the other 3 experimental regimens, suggesting 
that addition of PLD to the CT regimen does not improve 
outcome. Significant toxicities included grade 4 neutrope-
nia (70%), grade 3–4 thrombocytopenia (38%), grade 3–4 
anemia (20%), higher than observed with the standard arm. 
However rates of pulmonary, hepatic, gastrointestinal toxici-
ties and neuropathy were not significantly increased by the 
addition of PLD to the CT regimen.
The mild toxicity profile of PLD renders liposomal 
doxorubicin an ideal partner for combination regimens. 
At present, PLD is currently being investigated in combi-
nation with biological agents targeting tumor vasculature 
or other biological mechanisms relevant to tumor growth. 
For instance, PLD is being studied in combination with 
volocixumab, an antibody against α5β1 integrin complex 
(ClinicalTrials.gov identifier: NCT00635193); bevacizumab, 
an anti-VEGF antibody (ClinicalTrials.gov identifier: 
NCT00846612); AMG386, an angiopoietin inhibitor 
(ClinicalTrials.gov identifier: NCT00770536), panitumomab, 
an EGFR directed antibody (ClinicalTrials.gov identifier: 
NCT00861120); and others.
Combinations of PLD with novel cytotoxics included 
those with canfosfamide, EC145, a folate receptor targeted 
cytotoxic agent, and trabectidin. A phase III trial testing 
PLD in combination with trabectidin compared to PLD in 
650 women with recurrent OC has completed accrual, but has 
not yet been reported. Likewise, the combination PLD and 
canfosfamide has been compared to PLD as a single agent in 
a phase III trial enrolling 240 patients (unpublished).
Conclusions
In conclusion, the liposomal formulation of doxorubicin 
alters favorably the toxicity profile of the parent drug, ren-
dering PLD an easily tolerable agent. Due to the liposomal 
encapsulation, the agent is better delivered to tumor sites 
enabling enhanced exposure of cancer cells to DOX. Based 
on these properties, PLD has been investigated and found 
to be active in OC, leading to its approval for second-line 
therapy. Its testing in front-line regimens along with CT 
failed to improve survival. At the current time, PLD admin-
istered as a single agent is considered a very effective and 
tolerable option for second-line treatment of recurrent OC 
and therefore PLD is used as the comparator arm in many 
studies testing novel agents for recurrent OC. Its mild toxicity 
profile makes it an ideal partner for combination regimens 
with other cytotoxics, and more recently with biological 
agents, particularly with anti-angiogenic therapies. The 
recent results of the MITO-2 and Calypso trials suggest that 
the combination with carboplatin is an effective and nontoxic 
alternative for patients with platinum-sensitive OC. Pending 
results of trials testing PLD in combination with other 
biological agents, particularly anti-angiogenic drugs, may 
further strengthen its role in the treatment of recurrent OC.
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